Truist Securities Reiterates Buy on BioNTech, Raises Price Target to $155

Benzinga · 06/03 14:22
Truist Securities analyst Asthika Goonewardene reiterates BioNTech (NASDAQ:BNTX) with a Buy and raises the price target from $151 to $155.